Published in J Clin Oncol on July 01, 2003
Recent advances in neuroblastoma. N Engl J Med (2010) 7.86
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol (2012) 2.70
Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol (2009) 1.61
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol (2010) 1.57
Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med (2014) 1.21
Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer (2010) 1.19
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res (2011) 1.16
Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology (2012) 1.14
Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol (2009) 1.11
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr Blood Cancer (2013) 1.03
Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol (2009) 1.00
Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med (2009) 0.93
A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer (2010) 0.92
Nuclear medicine and multimodality imaging of pediatric neuroblastoma. Pediatr Radiol (2012) 0.91
Prognostic value of ¹⁸F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. Eur J Nucl Med Mol Imaging (2014) 0.91
Stem cell transplantation for neuroblastoma. Bone Marrow Transplant (2007) 0.89
Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors. Oncogene (2015) 0.89
MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis. Eur J Nucl Med Mol Imaging (2014) 0.83
123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev (2015) 0.80
(123)I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel. Eur J Nucl Med Mol Imaging (2016) 0.78
Neuroblastoma: issues in transplantation. Biol Blood Marrow Transplant (2012) 0.77
Advances in paediatric cancer treatment. Transl Pediatr (2014) 0.76
(18)F-DOPA PET/CT for assessment of response to induction chemotherapy in a child with high-risk neuroblastoma. Pediatr Radiol (2013) 0.75
Outcomes After Radiation Therapy to Metastatic Sites in Patients With Stage 4 Neuroblastoma. J Pediatr Hematol Oncol (2015) 0.75
Norepinephrine Transporter as a Target for Imaging and Therapy. J Nucl Med (2017) 0.75
Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on (123)I-MIBG SPECT predict the outcome? Eur J Nucl Med Mol Imaging (2017) 0.75
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol (2006) 4.87
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol (2009) 3.07
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
Regional copy number-independent deregulation of transcription in cancer. Nat Genet (2006) 2.33
Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol (2008) 2.23
Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol (2008) 2.23
Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol (2009) 2.21
Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet (2012) 2.02
Hypothalamic-pituitary lesions in pediatric patients: endocrine symptoms often precede neuro-ophthalmic presenting symptoms. J Pediatr (2012) 2.02
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 1.99
Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer. Breast Cancer Res Treat (2012) 1.97
Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol (2010) 1.88
Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat (2007) 1.86
Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. Cancer (2005) 1.85
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol (2002) 1.82
4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol (2006) 1.79
Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer (2006) 1.69
Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience. Cancer (2005) 1.67
Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol (2005) 1.66
Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer (2007) 1.63
High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatr Blood Cancer (2005) 1.59
Preoperative chemotherapy in children with high-risk medulloblastomas: a feasibility study. J Neurosurg (2005) 1.56
Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiother Oncol (2007) 1.50
Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study. Eur J Nucl Med Mol Imaging (2011) 1.50
Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol (2004) 1.46
Ocular adnexal lymphoma and Helicobacter pylori gastric infection. Am J Hematol (2010) 1.45
Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. Pediatr Blood Cancer (2013) 1.43
Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology. Int J Radiat Oncol Biol Phys (2006) 1.42
Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer Res (2010) 1.42
Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. Arthritis Rheum (2012) 1.41
Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol (2004) 1.40
Primary breast non-Hodgkin's lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors. Am J Hematol (2009) 1.40
Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet (2012) 1.37
Inflammatory myofibroblastic tumor in children: clinical review with anaplastic lymphoma kinase, Epstein-Barr virus, and human herpesvirus 8 detection analysis. J Pediatr Surg (2005) 1.37
Management of operable invasive breast cancer in women over the age of 70: long-term results of a large-scale single-institution experience. Ann Surg Oncol (2010) 1.36
Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol (2010) 1.36
Netrin-1 acts as a survival factor for aggressive neuroblastoma. J Exp Med (2009) 1.36
Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy--results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol (2003) 1.33
Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol (2005) 1.28
Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol (2009) 1.27
Extra-renal non-cerebral rhabdoid tumours. Pediatr Blood Cancer (2008) 1.26
Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer. EMBO J (2010) 1.25
Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol (2010) 1.24
Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer (2003) 1.24
Ophthalmologic and intraocular non-Hodgkin's lymphoma: a large single centre study of initial characteristics, natural history, and prognostic factors. Hematol Oncol (2004) 1.23
Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. Int J Radiat Oncol Biol Phys (2007) 1.23
Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J Clin Oncol (2003) 1.23
Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis (2006) 1.22
Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest Ophthalmol Vis Sci (2009) 1.22
Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res (2006) 1.19
Hepatic focal nodular hyperplasia in children previously treated for a solid tumor. Incidence, risk factors, and outcome. Cancer (2003) 1.19
Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol (2005) 1.18
Long-term risk of second malignant neoplasms after neuroblastoma in childhood: role of treatment. Int J Cancer (2003) 1.17
Chemothermotherapy in the management of retinoblastoma. Ophthalmology (2002) 1.16
Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab (2007) 1.16
Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study. J Clin Oncol (2006) 1.15
Impact of BRCA1 and BRCA2 variants on splicing: clues from an allelic imbalance study. Eur J Hum Genet (2009) 1.13
Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol (2005) 1.13
Chromatin assembly factor-1, a marker of clinical value to distinguish quiescent from proliferating cells. Cancer Res (2004) 1.13
Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol (2009) 1.13
Heterochromatin protein 1alpha: a hallmark of cell proliferation relevant to clinical oncology. EMBO Mol Med (2009) 1.12
Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer (2013) 1.12
Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol (2010) 1.09
Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol (2005) 1.08
High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies. Clin Cancer Res (2009) 1.08
Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging (2007) 1.08
Outcome of second malignancies after retinoblastoma: a retrospective analysis of 25 patients treated at the Institut Curie. Eur J Cancer (2004) 1.08
Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. Am J Clin Oncol (2009) 1.07
Hypercalcemia and childhood cancer: a 7-year experience. J Pediatr Hematol Oncol (2005) 1.07
Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas. Cancer Res (2005) 1.05
Outcome of suprarenal localized masses diagnosed during the perinatal period: a retrospective multicenter study. Cancer (2002) 1.05
Critical risk factors for intellectual impairment in children with posterior fossa tumors: the role of cerebellar damage. J Neurosurg (2004) 1.05
Conservative treatments of intraocular retinoblastoma. Ophthalmology (2008) 1.04
Medulloblastoma in young children. Pediatr Blood Cancer (2010) 1.03
High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res (2010) 1.02
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer (2009) 1.01
MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Mol Oncol (2008) 1.01
Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant. J Clin Oncol (2006) 1.01
Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol (2009) 1.00
Feasibility of ovarian tissue cryopreservation for prepubertal females with cancer. Pediatr Blood Cancer (2007) 1.00
High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control (2003) 0.98
Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma. PLoS One (2013) 0.98